Evidence map›Paper›PMID 38700322›Full record

Trial reportEuropean journal of neurology2024

Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.

Ioannis Vardakas, Johannes Dorst, André Huss, Benjamin Mayer, Tanja Fangerau, Daniela Taranu, Hayrettin Tumani, Makbule Senel

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02671682 (Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02671682 nacompletednot on this map

Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome

TypeinterventionalSponsorAlbert Christian Ludolph, Prof.Ran2016 to 2019Enrolled61ConditionsMultiple Sclerosis, Clinically Isolated SyndromeArmsImmunoadsorption, Plasmapheresis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ioannis VardakasDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID 0009-0005-5443-1142
Johannes DorstDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID 0000-0001-6352-0909
André HussDepartment of Neurology, University of Ulm, Ulm, Germany.
Benjamin MayerInstitute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
Tanja FangerauDepartment of Neurology, University of Ulm, Ulm, Germany.
Daniela TaranuDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID 0000-0001-9165-4437
Hayrettin TumaniDepartment of Neurology, University of Ulm, Ulm, Germany.
Makbule SenelDepartment of Neurology, University of Ulm, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe predictive value of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) for apheresis outcome in steroid-refractory multiple sclerosis (MS) relapse has not yet been evaluated.

methodsWe used pre- and postapheresis serum samples from 38 participants of the IAPEMS trial (clinicaltrials.gov: NCT02671682), which investigated the use of immunoadsorption versus plasma exchange for the treatment of steroid-refractory MS attacks. Response to apheresis was classified based on improvement on (i) the Expanded Disability Status Scale (EDSS), (ii) the affected functional system scores (FSS) of the EDSS, or (iii) the visual acuity for patients with optic neuritis, 4 weeks postapheresis. sNFL and sGFAP were measured by single molecule arrays.

resultsPreprocedural sGFAP levels could discriminate between responders and nonresponders, determined by FSS improvement (p = 0.017). In multivariate logistic regression analysis, younger age (odds ratio [OR] = 0.781, 95% confidence interval [CI] = 0.635-0.962, p = 0.020) and lower sGFAP levels (OR = 0.948, 95% CI = 0.903-0.995, p = 0.031) could predict response to apheresis in the overall cohort. We could observe a trend towards a favourable apheresis outcome with higher sNfL levels (OR = 1.413, 95% CI = 0.965-2.069, p = 0.076). Analysis of the sNfL-to-sGFAP ratio showed an OR of 1.924 (95% CI = 1.073-3.451, p = 0.028) for predicting apheresis response. The ratio showed a better predictive value than the individual parameters. Neither biomarker was affected by the number of steroid cycles preapheresis.

conclusionsLower sGFAP levels, a higher sNfL-to-sGFAP ratio, and younger age are associated with a favourable apheresis outcome.

Indexed as

Blood Component RemovalGlial Fibrillary Acidic ProteinNeurofilament ProteinsAdultBiomarkersFemaleHumansMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingPredictive Value of TestsRecurrenceTreatment OutcomeBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteinsclinical trialimmunoadsorptionMS relapsemultiple sclerosisplasma exchange

Identifiers

PMID38700322
PMCPMC11235822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.